Vascular Biogenics Ltd. (Nasdaq: VBLT) reported disappointing results from a Phase 3 GLOBE study in patients with recurrent glioblastoma sending the stock price plummeting $4.15 to close at $2.65.
Study results disappoint for Vascular Biogenics
March 08, 2018 at 16:10 PM EST